CN103379917B - 药物组合物 - Google Patents
药物组合物 Download PDFInfo
- Publication number
- CN103379917B CN103379917B CN201180063510.8A CN201180063510A CN103379917B CN 103379917 B CN103379917 B CN 103379917B CN 201180063510 A CN201180063510 A CN 201180063510A CN 103379917 B CN103379917 B CN 103379917B
- Authority
- CN
- China
- Prior art keywords
- methyl
- pharmaceutical composition
- amino
- group
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CNC*1=C[*+][*+](C2)C12N Chemical compound CNC*1=C[*+][*+](C2)C12N 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40883010P | 2010-11-01 | 2010-11-01 | |
| US61/408,830 | 2010-11-01 | ||
| US61/408830 | 2010-11-01 | ||
| PCT/US2011/058743 WO2012061360A2 (en) | 2010-11-01 | 2011-11-01 | Pharmaceutical compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103379917A CN103379917A (zh) | 2013-10-30 |
| CN103379917B true CN103379917B (zh) | 2016-10-12 |
Family
ID=46025057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180063510.8A Expired - Fee Related CN103379917B (zh) | 2010-11-01 | 2011-11-01 | 药物组合物 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9409896B2 (enExample) |
| EP (1) | EP2635307B1 (enExample) |
| JP (1) | JP5902188B2 (enExample) |
| KR (1) | KR20140022773A (enExample) |
| CN (1) | CN103379917B (enExample) |
| AU (1) | AU2011323594C1 (enExample) |
| BR (1) | BR112013010714A2 (enExample) |
| CA (1) | CA2816077C (enExample) |
| EA (1) | EA028054B1 (enExample) |
| ES (1) | ES2824898T3 (enExample) |
| HU (1) | HUE051133T2 (enExample) |
| IL (1) | IL225952A0 (enExample) |
| MX (1) | MX359366B (enExample) |
| NZ (1) | NZ609964A (enExample) |
| PH (1) | PH12013500882A1 (enExample) |
| PT (1) | PT2635307T (enExample) |
| SG (2) | SG10201508982TA (enExample) |
| UA (1) | UA114469C2 (enExample) |
| WO (1) | WO2012061360A2 (enExample) |
| ZA (1) | ZA201303177B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2781666C (en) | 2009-11-23 | 2017-02-21 | Cubist Pharmaceuticals, Inc. | Lipopeptide compositions and related methods |
| EA027791B1 (ru) * | 2010-11-24 | 2017-09-29 | Мелинта Терапьютикс, Инк. | Фармацевтические композиции |
| WO2013182070A1 (zh) * | 2012-06-08 | 2013-12-12 | 四川贝力克生物技术有限责任公司 | 一种用于预防或治疗分支杆菌疾病的药物 |
| SG11201605580RA (en) | 2014-01-10 | 2016-10-28 | Anaptysbio Inc | Antibodies directed against interleukin-33 (il-33) |
| WO2021133279A1 (en) * | 2019-12-26 | 2021-07-01 | Santa Farma İlaç Sanayi̇ A.Ş. | A solid oral pharmaceutical gemifloxacin mesylate composition with improved release pattern and disintegration mechanism |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1207895A (zh) * | 1997-08-12 | 1999-02-17 | 陕西省西安制药厂 | 一种克拉霉素胶囊 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ID16956A (id) | 1996-05-24 | 1997-11-27 | Schering Corp | Komposisi antijamur dengan ketersediaan hayati yang tertingkatkan |
| DK0996429T3 (da) * | 1997-10-27 | 2003-05-26 | Merck Patent Gmbh | Faste opløsninger og faste dispersioner i vand tungtopløselige lægemidler |
| GB2331458B (en) | 1997-11-21 | 2002-07-31 | Gursharan Singh Moonga | Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine |
| KR19990080453A (ko) * | 1998-04-17 | 1999-11-05 | 성재갑 | 비가역성 hiv 프로테아제 억제제를 함유하는 약제학적 조성물 |
| US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US7527807B2 (en) * | 2000-06-21 | 2009-05-05 | Cubist Pharmaceuticals, Inc. | Compositions and methods for increasing the oral absorption of antimicrobials |
| US6696426B2 (en) * | 2000-08-22 | 2004-02-24 | Pharmacia Corporation | Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems |
| US20020119196A1 (en) | 2000-12-21 | 2002-08-29 | Narendra Parikh | Texture masked particles containing an active ingredient |
| ES2739852T3 (es) | 2001-07-06 | 2020-02-04 | Veloxis Pharmaceuticals As | Aglomeración controlada |
| US7842791B2 (en) * | 2002-12-19 | 2010-11-30 | Nancy Jean Britten | Dispersible pharmaceutical compositions |
| TWI378092B (en) | 2003-06-03 | 2012-12-01 | Rib X Pharmaceuticals Inc | Biaryl heterocyclic compounds and methods of making and using the same |
| US20060270680A1 (en) | 2003-06-03 | 2006-11-30 | Goldberg Joel A | Sulfonamide compounds and methods of making and using the same |
| KR20060085686A (ko) * | 2003-10-10 | 2006-07-27 | 라이프사이클 파마 에이/에스 | 피브레이트를 포함하는 고형 제제 |
| KR100854211B1 (ko) | 2003-12-18 | 2008-08-26 | 동아제약주식회사 | 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물 |
| KR20050104152A (ko) * | 2004-04-28 | 2005-11-02 | 최승호 | 경구용 약물의 흡수를 증진하는 약제학적 조성물 |
| NZ580951A (en) * | 2005-04-29 | 2011-06-30 | Cubist Pharm Inc | Therapeutic compositions |
| EP1904489B1 (en) * | 2005-06-08 | 2011-01-26 | Rib-X Pharmaceuticals, Inc. | Process for the synthesis of triazoles |
| EP1998788A4 (en) * | 2006-03-01 | 2011-08-03 | Ruey J Yu | COMPOSITIONS AND METHODS FOR THE TOPIC TREATMENT OF DERMATOLOGICAL DISORDERS RESPONSIBLE FOR TAR |
| TW200800179A (en) * | 2006-03-06 | 2008-01-01 | Wyeth Corp | Pharmaceutical formulations of an anhydrous crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| US20100234288A1 (en) * | 2006-03-27 | 2010-09-16 | Panacea Biotec Ltd | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION ON THE BASIS OF RELEASE SYSTEM COMPRISING AN ACID-SOLUBLE POLYMER AND A pH-DEPENDENT POLYMER |
| WO2008085913A1 (en) * | 2007-01-04 | 2008-07-17 | Rib-X Pharmaceuticals, Inc. | Methods for treating, preventing, or reducing the risk of opthalmic, otic, and nasal infections |
| US20090061009A1 (en) * | 2007-08-29 | 2009-03-05 | Joseph Schwarz | Composition and Method of Treatment of Bacterial Infections |
| WO2010046933A2 (en) * | 2008-10-22 | 2010-04-29 | Rubicon Research Private Limited | Pharmaceutical compositions of taste-masked linezolid |
-
2011
- 2011-11-01 WO PCT/US2011/058743 patent/WO2012061360A2/en not_active Ceased
- 2011-11-01 ES ES11838664T patent/ES2824898T3/es active Active
- 2011-11-01 SG SG10201508982TA patent/SG10201508982TA/en unknown
- 2011-11-01 EP EP11838664.8A patent/EP2635307B1/en active Active
- 2011-11-01 MX MX2013004711A patent/MX359366B/es active IP Right Grant
- 2011-11-01 UA UAA201306779A patent/UA114469C2/uk unknown
- 2011-11-01 PT PT118386648T patent/PT2635307T/pt unknown
- 2011-11-01 CN CN201180063510.8A patent/CN103379917B/zh not_active Expired - Fee Related
- 2011-11-01 US US13/882,698 patent/US9409896B2/en active Active
- 2011-11-01 JP JP2013536921A patent/JP5902188B2/ja not_active Expired - Fee Related
- 2011-11-01 KR KR1020137013955A patent/KR20140022773A/ko not_active Abandoned
- 2011-11-01 NZ NZ609964A patent/NZ609964A/en not_active IP Right Cessation
- 2011-11-01 PH PH1/2013/500882A patent/PH12013500882A1/en unknown
- 2011-11-01 CA CA2816077A patent/CA2816077C/en active Active
- 2011-11-01 EA EA201390646A patent/EA028054B1/ru not_active IP Right Cessation
- 2011-11-01 AU AU2011323594A patent/AU2011323594C1/en not_active Ceased
- 2011-11-01 BR BR112013010714A patent/BR112013010714A2/pt not_active IP Right Cessation
- 2011-11-01 SG SG2013033865A patent/SG190117A1/en unknown
- 2011-11-01 HU HUE11838664A patent/HUE051133T2/hu unknown
-
2013
- 2013-04-25 IL IL225952A patent/IL225952A0/en unknown
- 2013-04-30 ZA ZA2013/03177A patent/ZA201303177B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1207895A (zh) * | 1997-08-12 | 1999-02-17 | 陕西省西安制药厂 | 一种克拉霉素胶囊 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012061360A2 (en) | 2012-05-10 |
| UA114469C2 (uk) | 2017-06-26 |
| EP2635307A2 (en) | 2013-09-11 |
| SG10201508982TA (en) | 2015-12-30 |
| NZ609964A (en) | 2015-08-28 |
| AU2011323594A1 (en) | 2013-05-23 |
| PH12013500882A1 (en) | 2020-10-19 |
| US9409896B2 (en) | 2016-08-09 |
| IL225952A0 (en) | 2013-07-31 |
| AU2011323594B2 (en) | 2016-12-22 |
| CA2816077C (en) | 2021-08-10 |
| EA028054B1 (ru) | 2017-10-31 |
| EP2635307A4 (en) | 2014-11-05 |
| ZA201303177B (en) | 2018-12-19 |
| EA201390646A1 (ru) | 2014-01-30 |
| EP2635307B1 (en) | 2020-07-29 |
| CA2816077A1 (en) | 2012-05-10 |
| JP5902188B2 (ja) | 2016-04-13 |
| HUE051133T2 (hu) | 2021-03-01 |
| US20140094463A1 (en) | 2014-04-03 |
| JP2013542226A (ja) | 2013-11-21 |
| BR112013010714A2 (pt) | 2024-01-16 |
| SG190117A1 (en) | 2013-06-28 |
| WO2012061360A3 (en) | 2012-07-12 |
| PT2635307T (pt) | 2020-11-03 |
| MX2013004711A (es) | 2013-08-29 |
| CN103379917A (zh) | 2013-10-30 |
| AU2011323594C1 (en) | 2017-06-01 |
| ES2824898T3 (es) | 2021-05-13 |
| KR20140022773A (ko) | 2014-02-25 |
| MX359366B (es) | 2018-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5902188B2 (ja) | 薬学的組成物 | |
| TWI641372B (zh) | 使用抗生素治療超重和肥胖患者感染的方法 | |
| JP2013542226A5 (enExample) | ||
| WO2011080570A2 (en) | Extended release pharmaceutical composition comprising linezolid and process for preparing the same | |
| AU2016234893A1 (en) | Pharmaceutical Compositions | |
| KR102936624B1 (ko) | 엔잘루타마이드를 포함하는 무정형 고체 분산체, 그를 포함하는 경구 투여용 약제학적 제제 | |
| KR101944124B1 (ko) | 약학 조성물 | |
| HK40114583A (en) | Eed inhibitor solid dispersion, oral formulation comprising same, and preparation method therefor | |
| WO2014126541A1 (en) | Pharmaceutical compositions used in treating bacterial infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: American Connecticut Applicant after: RIB-X PHARMACEUTICALS, INC. Address before: American Connecticut Applicant before: RIB-X Pharmaceuticals |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: RIB-X PHARMACEUTICAL COMPANY TO: RIB X PHARMACEUTICALS INC. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20161012 Termination date: 20191101 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |